Effect Modification by Indication to the Risks of Major Thromboembolic Adverse Events in Patients Receiving Intravitreal Anti-Vascular Endothelial Growth Factor Treatment: A Population-Based Retrospective Cohort Study
- 1 March 2022
- journal article
- research article
- Published by Springer Nature in BioDrugs
- Vol. 36 (2) , 205-216
Abstract
Background The association between intravitreal anti-vascular endothelial growth factor (anti-VEGF) treatment and the risk of major thromboembolic adverse events (TAEs) remains under debate. This study aimed to examine associated risks of TAEs in patients receiving intravitreal anti-VEGF treatment, and effect modification by different indications. Methods This retrospective cohort study analyzed Taiwan’s National Health Insurance Database during 2011–2017 to identify neovascular age-related macular degeneration (nAMD) or diabetic macular edema (DME) patients newly receiving intravitreal aflibercept or ranibizumab. We followed up patients for 2 years, or until the occurrence of TAEs, including ischemic heart disease, ischemic stroke, transient ischemic attack, deep vein thrombosis, and pulmonary embolism, death, or the end of the study period (i.e., 31 December 2018). We compared the risk of TAEs between patients with aflibercept and ranibizumab using Cox-proportional hazard models. We examined statistical interactions between the anti-VEGF treatment (i.e., ranibizumab and aflibercept) and indications (i.e., nAMD and DME) with regard to the outcome of TAEs. Results We included 12,215 nAMD and 7532 DME patients. Among nAMD patients, those receiving aflibercept had lower risk of TAEs (adjusted hazard ratio [HR] 0.85; 95% CI 0.77–0.94) compared with those receiving ranibizumab. However, among DME patients, those receiving aflibercept had no differences in the risk of TAEs (1.14; 0.97–1.35) compared with those receiving ranibizumab. Among patients treated with ranibizumab, the DME group had a higher risk of TAEs than the nAMD group (HR 1.15; 95% CI 1.03–1.28); similar results were observed in patients treated with aflibercept (HR 1.53; 95% CI 1.27–1.85). When DME patients were treated with aflibercept, the risk of TAEs was 31% higher than when nAMD patients were treated with ranibizumab (HR 1.31; 95% CI 1.09–1.56; p < 0.05). The p-value for statistical interaction between the anti-VEGF treatment and indications was 0.0033. Conclusions Patients treated with aflibercept or ranibizumab for different indications may be associated with varying risk of TAEs. The findings provide evidence to support treatment selection, taking indications and TAE risk into consideration.Keywords
Funding Information
- Ministry of Science and Technology of Taiwan (107-2320-B-006-070-MY3)
This publication has 38 references indexed in Scilit:
- Systemic thromboembolic adverse events in patients treated with intravitreal anti-VEGF drugs for neovascular age-related macular degeneration: an overviewExpert Opinion on Drug Safety, 2014
- Different effects of intravitreally injected ranibizumab and aflibercept on retinal and choroidal tissues of monkey eyesBritish Journal of Ophthalmology, 2014
- Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literatureEye, 2013
- Intravitreal Aflibercept (VEGF Trap-Eye) in Wet Age-related Macular DegenerationOphthalmology, 2012
- Eyeing Macular Degeneration — A Few Inflammatory RemarksNew England Journal of Medicine, 2012
- Validation of the national health insurance research database with ischemic stroke cases in TaiwanPharmacoepidemiology and Drug Safety, 2010
- ANGIOGENIC AND INFLAMMATORY MARKERS IN THE INTRAOCULAR FLUID OF EYES WITH DIABETIC MACULAR EDEMA AND INFLUENCE OF THERAPY WITH BEVACIZUMABRetina, 2010
- Age-Related Macular DegenerationNew England Journal of Medicine, 2008
- PlGF-1 and VEGFR-1 Pathway Regulation of the External Epithelial Hemato-Ocular BarrierOphthalmic Research, 2008
- Vitreous Levels of Pigment Epithelium–Derived Factor and Vascular Endothelial Growth Factor Are Related to Diabetic Macular EdemaOphthalmology, 2006